http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.
-
BioNTech SE (BNTX) and Pfizer (PFE) Collaborate with SAR's Biovac for Vaccine Distribution in Africa
-
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
-
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa
-
Pfizer and BioNTech Announce Collaboration with Biovac to Manufacture and Distribute COVID-19 Vaccine Doses within Africa
-
BioNTech SE (BNTX) to Acquire Kite’s (GILD) Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
-
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
-
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
-
U.S. FDA sets January target to decide on approval of Pfizer's COVID-19 shot
-
Pfizer (PFE), BioNTech (BNTX) to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations
-
Pfizer (PFE), BioNTech (BNTX) Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
-
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
-
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents
-
Pfizer (PFE) Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech (BNTX) COVID-19 Vaccine in Older Adults
-
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults
-
Pfizer (PFE), BioNTech SE (BNTX) to Supply EU with 1.8 Billion Additional Doses of COVID-19 Vaccine
-
Pfizer (PFE), BioNTech (BNTX) Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine
-
Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine
-
Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®
-
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®
-
Pfizer and BioNTech to Supply the European Union with up to 1.8 Billion Additional Doses of COMIRNATY®
-
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
-
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
-
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents
-
Pfizer (PFE) and BioNTech (BNTX) Initiate Rolling Submission of BLA for U.S. FDA Approval of Their COVID-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID-19 Vaccine
-
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine
-
Pfizer (PFE) and BioNTech (BNTX) to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games
-
Pfizer (PFE), BioNTech (BNTX) Submit Request to Expand Conditional Marketing Authorization of Vaccine in EU to Adolescents
-
Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY® in the EU to Adolescents
-
Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY® in the EU to Adolescents
-
Pfizer (PFE) and BioNTech (BNTX) to Supply EU with 100 Million Additional Doses of COVID-19 Vaccine
-
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
-
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
-
Pfizer (PFE) and BioNTech (BNTX) Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine 100% Effective in Adolescents 12 to 15 Years of Age, Trial Shows
-
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
-
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
-
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

